These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22393089)

  • 21. Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-A prospective trial.
    Wagner LM; Kremer N; Gelfand MJ; Sharp SE; Turpin BK; Nagarajan R; Tiao GM; Pressey JG; Yin J; Dasgupta R
    Cancer; 2017 Jan; 123(1):155-160. PubMed ID: 27563842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective comparative study of ultrasonography, contrast-enhanced MRI and 18F-FDG PET/CT for preoperative detection of axillary lymph node metastasis in breast cancer patients.
    Guney IB; Dalci K; Teke ZT; Kucuker KA
    Ann Ital Chir; 2020; 91():458-464. PubMed ID: 32213685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
    Barranger E; Grahek D; Antoine M; Montravers F; Talbot JN; Uzan S
    Ann Surg Oncol; 2003 Jul; 10(6):622-7. PubMed ID: 12839846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
    Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer.
    Pargaonkar AS; Beissner RS; Snyder S; Speights VO
    Arch Pathol Lab Med; 2003 Jun; 127(6):701-5. PubMed ID: 12741893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer - a retrospective comparative study with PET/CT and breast MRI.
    Sae-Lim C; Wu WP; Chang MC; Lai HW; Chen ST; Chou CT; Liao CY; Huang HI; Chen ST; Chen DR; Hung CL
    World J Surg Oncol; 2024 Jan; 22(1):12. PubMed ID: 38183069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
    Futamura M; Asano T; Kobayashi K; Morimitsu K; Nawa M; Kanematsu M; Morikawa A; Mori R; Yoshida K
    World J Surg Oncol; 2015 Feb; 13():49. PubMed ID: 25885028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
    Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
    BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
    Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
    Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging--initial findings.
    Stadnik TW; Everaert H; Makkat S; Sacré R; Lamote J; Bourgain C
    Eur Radiol; 2006 Oct; 16(10):2153-60. PubMed ID: 16670863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical utility of combining pre-operative axillary ultrasonography and fine needle aspiration cytology with radionuclide guided sentinel lymph node biopsy in breast cancer patients with palpable axillary lymph nodes.
    Usmani S; Ahmed N; Al Saleh N; abu Huda F; Amanguno HG; Amir T; al Kandari F
    Eur J Radiol; 2015 Dec; 84(12):2515-20. PubMed ID: 26474908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
    Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Axillary SUV
    Karabacak U; Turkan H; Coskun G; Mollaoglu MC; Hasbek Z; Karadayi K
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):374-379. PubMed ID: 37190706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.